Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor respons… Read more
Eikon Therapeutics, Inc. Common Stock (EIKN) - Total Liabilities
Latest total liabilities as of September 2025: $1.45 Billion USD
Based on the latest financial reports, Eikon Therapeutics, Inc. Common Stock (EIKN) has total liabilities worth $1.45 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eikon Therapeutics, Inc. Common Stock - Total Liabilities Trend (2023–2024)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Eikon Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Eikon Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TI Fluid Systems PLC
LSE:TIFS
|
UK | GBX2.05 Billion |
|
Nuveen Multi-Asset Income Fund
NYSE:NMAI
|
USA | $230.01 Million |
|
Together Startup Network Ltd
TA:TGTR
|
Israel | ILA56.03 Million |
Liability Composition Analysis (2023–2024)
This chart breaks down Eikon Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eikon Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eikon Therapeutics, Inc. Common Stock (2023–2024)
The table below shows the annual total liabilities of Eikon Therapeutics, Inc. Common Stock from 2023 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.06 Billion | +22.62% |
| 2023-12-31 | $867.08 Million | -- |